| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 952 | 778 | 800 | 811 | 1,223 | 1,029 | 989 | 1,086 | 974 | 986 | 1,025 | 1,098 | 1,242 | 1,193 | 1,564 | 1,585 | 1,557 | 1,483 | 1,673 | 1,784 | 1,621 | 1,712 | 1,765 | 1,885 | 2,060 | 1,808 | 1,945 | 2,223 | 2,476 | 2,217 | 2,384 | 3,020 | 3,929 | 3,516 | 3,551 | 4,135 | 3,912 | 4,543 | 3,604 | 3,826 | 4,415 | 3,990 | 4,356 |
| Expenses | 653 | 606 | 727 | 615 | 740 | 719 | 706 | 762 | 738 | 735 | 786 | 836 | 937 | 886 | 982 | 1,160 | 1,137 | 1,029 | 1,174 | 1,307 | 1,247 | 1,284 | 1,363 | 1,459 | 1,476 | 1,427 | 1,515 | 1,733 | 1,911 | 1,783 | 1,894 | 2,624 | 2,820 | 2,741 | 2,769 | 3,051 | 3,013 | 2,813 | 2,905 | 3,070 | 3,339 | 3,193 | 3,472 |
| EBITDA | 300 | 172 | 73 | 196 | 483 | 309 | 283 | 324 | 236 | 250 | 239 | 262 | 306 | 307 | 582 | 425 | 420 | 454 | 499 | 477 | 373 | 428 | 402 | 427 | 584 | 380 | 430 | 489 | 565 | 434 | 490 | 396 | 1,109 | 775 | 782 | 1,084 | 900 | 1,730 | 699 | 756 | 1,077 | 797 | 884 |
| Operating Profit % | 21 % | 20 % | 6 % | 22 % | 21 % | 27 % | 25 % | 27 % | 20 % | 21 % | 19 % | 21 % | 20 % | 21 % | 26 % | 25 % | 26 % | 29 % | 25 % | 25 % | 20 % | 24 % | 22 % | 21 % | 20 % | 19 % | 18 % | 20 % | 21 % | 17 % | 18 % | 11 % | 25 % | 20 % | 18 % | 14 % | 22 % | 17 % | 18 % | 19 % | 23 % | 18 % | 19 % |
| Depreciation | 59 | 59 | 61 | 64 | 65 | 66 | 68 | 70 | 73 | 99 | 94 | 97 | 95 | 99 | 112 | 117 | 120 | 124 | 132 | 144 | 152 | 167 | 178 | 186 | 184 | 195 | 202 | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 415 | 407 | 405 | 420 | 425 | 436 | 455 | 473 |
| Interest | 0 | 4 | 3 | 2 | 21 | 6 | 7 | 9 | 5 | 16 | 14 | 15 | 17 | 18 | 19 | 19 | 16 | 17 | 14 | 18 | 17 | 13 | 7 | 5 | 34 | 20 | 23 | 15 | 11 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 |
| Profit Before Tax | 249 | 165 | 20 | 141 | 409 | 238 | 208 | 245 | 159 | 135 | 132 | 150 | 193 | 190 | 451 | 289 | 284 | 313 | 354 | 315 | 204 | 249 | 218 | 236 | 366 | 166 | 206 | 269 | 343 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 |
| Tax | 32 | 34 | 18 | 19 | 55 | 55 | 42 | 54 | 10 | 38 | 43 | 36 | 41 | 52 | 73 | 46 | 41 | 85 | 100 | 85 | 45 | 81 | 22 | 49 | 69 | 57 | 46 | 49 | 59 | 30 | 147 | -5 | 82 | 35 | 42 | 55 | 96 | 284 | 71 | 75 | 27 | 8 | 39 |
| Net Profit | 217 | 131 | 2 | 122 | 354 | 182 | 167 | 191 | 148 | 98 | 89 | 114 | 153 | 138 | 378 | 243 | 243 | 228 | 254 | 230 | 159 | 168 | 195 | 187 | 296 | 108 | 160 | 220 | 284 | 167 | 82 | -21 | 415 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 |
| EPS in ₹ | 10.08 | 6.31 | -0.54 | 5.30 | 16.97 | 8.49 | 7.48 | 8.72 | 6.49 | 1.38 | 1.17 | 1.56 | 2.21 | 1.02 | 3.00 | 3.67 | 3.61 | 1.74 | 1.82 | 1.71 | 1.04 | 1.26 | 1.39 | 1.42 | 2.13 | 0.71 | 1.16 | 1.57 | 2.00 | 1.21 | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 | 2.88 | 0.26 | 0.66 |
Biocon
Biocon
420.95
+9.80
(2.38%)
Key Fundamentals
Market Cap
54,969.30 Cr
EPS
8.46
PE Ratio
72.11
Dividend Yield
0.11 %
Industry
Healthcare 52 Week High
423.10
52 Week Low
291.00
PB Ratio
2.05
Debt to Equity
0.84
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from16 analysts
Actual
Company News
View All News
Biocon Limited addressed media reports regarding potential merger of its unlisted subsidiary Biocon Biologics Limited, confirming that a Board-constituted committee is still evaluating strategic restructuring options including merger, IPO and share swap possibilities. The company stated no material event requiring disclosure exists at this stage, reiterating its commitment to make appropriate disclosures when required under applicable laws.
Biocon shares jumped 2.6% to a new 52-week high of Rs 416.85 following reports that the company is evaluating an internal merger of its biosimilars arm, Biocon Biologics, with the parent entity. The potential $4.5 billion transaction is being reviewed alongside alternative options including an IPO and share swap with minority investors. Biocon is restructuring its wholly owned subsidiary to unlock shareholder value and reduce acquisition-related debt of $1.2 billion from the 2022 acquisition of Viatris' global biosimilars business for $3.3 billion. Chairperson Kiran Mazumdar-Shaw confirmed the company is exploring all value creation routes and has appointed Morgan Stanley to identify the best alternative. Biocon owns a 90.2% stake in Biocon Biologics, with Serum Institute of Life Sciences holding 5.97%. The IPO route has been deprioritized due to market volatility, with the board now examining a merger as a more viable alternative.
SBI Mutual Fund acquired 3,70,150 shares of Biocon on November 11, 2025, through market purchase, increasing its total holding to 6,68,65,887 shares representing 5.0013% of the company's paid-up share capital. Prior to this acquisition, SBI Mutual Fund held 6,64,95,737 shares (4.9736% stake) in Biocon. The acquisition pushed the fund's holding above the 5% threshold, triggering disclosure requirements. Biocon's total equity share capital consists of 1,33,69,63,635 equity shares with a face value of Rs. 5 each.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,763.90 | #1 4,21,587.10 | 40.19 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 72.45 | |
6,518.50 | 1,72,859.90 | 69.56 | 9,712.00 | 18.67 | 2,191 | 35.10 | 50.21 | |
3,819.40 | 1,29,685.50 | 60.73 | 11,539.40 | 6.99 | 1,911 | 30.46 | 68.95 | |
1,535.60 | 1,23,756.00 | 22.77 | 28,409.50 | 7.12 | 5,291 | 3.71 | 49.08 | |
1,244.40 | 1,03,992.90 | #1 18.11 | 33,741.20 | 16.73 | 5,725 | -0.38 | 52.18 | |
934.75 | 95,033.80 | 18.89 | 23,511.00 | 18.55 | 4,615 | 34.60 | 34.63 | |
2,052.10 | 93,876.80 | 21.59 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 64.79 | |
2,247.00 | 93,576.50 | 52.74 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 31.45 | |
1,236.90 | 71,003.00 | 20.93 | 32,345.60 | 9.43 | 3,484 | 3.81 | 75.20 | |
5,723.00 | 68,421.10 | 28.40 | 13,458.30 | 3.70 | 2,216 | 10.98 | 64.57 |
Growth Rate
Revenue Growth
5.43 %
Net Income Growth
10.14 %
Cash Flow Change
37.49 %
ROE
0.58 %
ROCE
1.95 %
EBITDA Margin (Avg.)
-0.38 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Fixed Assets | 1,630 | 1,749 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 |
| Current Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,823 | 5,325 | 7,600 | 8,382 | 12,334 | 15,179 | 16,286 |
| Capital Work in Progress | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 |
| Investments | 230 | 901 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 |
| Other Assets | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,311 | 7,406 | 8,127 | 13,189 | 16,434 | 17,199 |
| Total Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Current Liabilities | 1,555 | 1,666 | 1,678 | 2,141 | 3,038 | 4,008 | 4,210 | 3,828 | 8,511 | 15,359 | 14,334 |
| Non Current Liabilities | 1,378 | 2,493 | 2,502 | 2,200 | 2,448 | 3,053 | 5,805 | 7,096 | 21,043 | 15,437 | 16,751 |
| Total Equity | 3,443 | 4,300 | 5,214 | 5,649 | 6,707 | 7,383 | 8,508 | 9,470 | 22,489 | 25,275 | 27,713 |
| Reserve & Surplus | 3,171 | 3,992 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 |
| Share Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 | 2,004 |
| Investing Activities | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 | -203 |
| Operating Activities | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | 2,954 | 4,061 |
| Financing Activities | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 | -1,854 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 60.67 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 54.45 % | 54.45 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 7.96 % | 6.55 % | 5.63 % | 5.90 % | 5.93 % | 5.66 % | 5.66 % | 6.04 % | 6.61 % |
| DIIs | 6.65 % | 6.89 % | 6.87 % | 6.83 % | 7.79 % | 7.30 % | 7.76 % | 8.63 % | 11.90 % | 12.56 % | 14.08 % | 14.51 % | 13.68 % | 14.30 % | 14.44 % | 15.37 % | 15.72 % | 22.82 % | 22.10 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.89 % | 11.03 % | 11.49 % | 11.37 % | 10.87 % | 10.72 % | 12.07 % | 12.46 % | 13.21 % | 13.34 % | 13.61 % | 14.47 % | 15.53 % | 14.63 % | 14.57 % | 14.07 % | 13.63 % | 12.58 % | 12.71 % |
| Others | 21.79 % | 21.44 % | 21.00 % | 21.16 % | 20.70 % | 21.35 % | 19.54 % | 18.27 % | 14.26 % | 13.46 % | 3.70 % | 3.83 % | 4.52 % | 4.53 % | 4.42 % | 4.27 % | 4.34 % | 4.10 % | 4.12 % |
| No of Share Holders | 0 | 3,11,349 | 3,38,815 | 3,63,447 | 3,64,502 | 3,47,911 | 3,41,016 | 3,69,816 | 4,11,086 | 4,12,441 | 4,15,046 | 4,34,339 | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 | 4,30,217 | 4,13,191 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 1 | 1 | 0.00 | 0.00 | 0.5 | 1.5 | 0.5 | 0.5 |
| Dividend Yield (%) | 0.00 | 1.01 | 0.33 | 0.37 | 0.00 | 0.00 | 0.25 | 0.57 | 0.15 | 0.12 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Jun 2019 |  Bonus | 1:1 | 12 Jun 2019 | 271.45 | 257.90 |
| 01 Jul 2022 |  Dividend | ₹ 0.50 /share | 30 Jun 2022 | 382.30 | 308.40 |
| 07 Jul 2023 | Dividend | ₹ 1.50 /share | 07 Jul 2023 | 240.45 | 259.50 |
| 05 Jul 2024 | Dividend | ₹ 0.50 /share | 05 Jul 2024 | 311.90 | 361.10 |
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 311.90 | 339.20 |
| 30 Oct 2024 |  Quarterly Result Announcement | NA | 30 Oct 2024 | 370.65 | 326.85 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 372.95 | 355.70 |
| 08 May 2025 | Quarterly Result Announcement | NA | 08 May 2025 | 339.10 | 346.50 |
| 04 Jul 2025 | Dividend | ₹ 0.50 /share | 04 Jul 2025 | 346.50 | 374.40 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 372.05 | 360.60 |
| 08 Aug 2025 | Annual General Meeting | NA | 08 Aug 2025 | 346.50 | 364.20 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 352.25 | 382.15 |
Announcements
Rumour verification - Regulation 30(11)
3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication4 days ago
4 days agoDisclosures under Reg. 29(1) of SEBI (SAST) Regulations 20114 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Monitoring Agency Report6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Raising of Funds6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements6 days ago
6 days agoOutcome Of Board Meeting _ Early Full Redemption Of Non-Convertible Debentures6 days ago
6 days agoOutcome Of Board Meeting Held On November 11 20256 days ago
6 days agoBoard Meeting Outcome for Outcome Of Board Meeting Held On November 11 20256 days ago
6 days agoFinancial Results For Quarter And Half Year Ended 30 September 20256 days ago
6 days agoNotification9 days ago
9 days agoUpdate on board meetingNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Credit RatingOct 30, 2025
Oct 30, 2025Intimation Of Change In Status And Name Of Step-Down Subsidiary Of The CompanyOct 30, 2025
Oct 30, 2025Intimation Of Change In Name Of Step-Down Subsidiaries Of The CompanyOct 23, 2025
Oct 23, 2025Press ReleaseOct 23, 2025
Oct 23, 2025Press ReleaseOct 16, 2025
Oct 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Company StatementOct 11, 2025
Oct 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 09, 2025
Oct 09, 2025Submission Of Copy Of Biocon India Limited Employees Welfare Trust Amendment DeedOct 09, 2025
Oct 09, 2025Notification To Stock ExchangesOct 07, 2025
Oct 07, 2025Board Meeting Intimation for Intimation Of The Date Of Board MeetingOct 06, 2025
Oct 06, 2025Board Meeting Outcome for Early Redemption Of NcdsOct 01, 2025
Oct 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 01, 2025
Oct 01, 2025Board Meeting Intimation for Proposed Early Redemption Of Unlisted Secured Rated Redeemable Non-Convertible Debentures (Ncds).Sep 28, 2025
Sep 28, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement Under Regulation 30 - Receipt Of Show Cause NoticeSep 25, 2025
Sep 25, 2025Buyback Of Commercial PaperSep 19, 2025
Sep 19, 2025Intimation Of Record Date For Buy Back Of Listed Commercial Paper Issued By The CompanySep 17, 2025
Sep 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 17, 2025
Sep 17, 2025Letters To Shareholders Under 100 Days Campaign - Saksham NiveshakSep 13, 2025
Sep 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 12, 2025
Sep 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 11, 2025
Sep 11, 2025Email Communication To Shareholders Under 100 Days Campaign - Saksham NiveshakSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 09, 2025
Sep 09, 2025Board Meeting Outcome for Outcome Of Board MeetingSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 05, 2025
Sep 05, 2025Company StatementSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 29, 2025
Aug 29, 2025Notification To Stock ExchangesAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Aug 20, 2025Transcript Of Earnings Call Q1 FY26Aug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 14, 2025
Aug 14, 2025Mutual Fund Holdings
Kotak Arbitrage Fund Direct-Growth 
Quant ELSS Tax Saver Fund Direct-Growth 
HSBC Midcap Fund Direct-Growth 
Mirae Asset Midcap Fund Direct - Growth 
Nippon India Multi Cap Fund Direct-Growth 
ICICI Prudential Value Direct-Growth 
Canara Robeco Large and Mid Cap Fund Direct-Growth 
Tata Arbitrage Fund Direct - Growth 
Sundaram Aggressive Hybrid Fund Direct-Growth 
Bandhan Large & Mid Cap Fund Direct-Growth 
Axis Innovation Fund Direct-Growth 
ITI Mid Cap Fund Direct - Growth 
HDFC Arbitrage Fund Wholesale Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
Bajaj Finserv Flexi Cap Fund Direct-Growth 
Mahindra Manulife Focused Fund Direct - Growth 
UTI Arbitrage Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 73.99
ATR(14)
Volatile 10.03
STOCH(9,6)
Overbought 83.70
STOCH RSI(14)
Overbought 92.21
MACD(12,26)
Bullish 4.27
ADX(14)
Strong Trend 30.67
UO(9)
Bearish 63.30
ROC(12)
Uptrend And Accelerating 12.41
WillR(14)
Overbought -18.54
About Biocon
Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years,
10 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
